Company Filing History:
Years Active: 2003-2009
Title: Innovator Spotlight: Fatima Emitsel Yakubu-Madus
Introduction
Fatima Emitsel Yakubu-Madus is an accomplished inventor based in Indianapolis, IN, with a keen interest in medical innovations. With a total of 3 patents to her name, she has made significant contributions to the field of healthcare, particularly in the realm of diabetes treatment.
Latest Patents
1. "Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagonlike peptide-1 and agonists thereof": This patent showcases Yakubu-Madus's novel approach to treating non-insulin dependent diabetes mellitus by combining thiazolidinediones (TZD) with agonists of glucagon-like peptide-1 (GLP-1). This innovative method improves glycemic control in Type II diabetic patients while minimizing side effects associated with existing therapies.
2. "Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes": Another groundbreaking patent by Yakubu-Madus, this invention focuses on leveraging the synergistic effects of TZD and GLP-1 agonists to address metabolic instability in diabetic patients. By co-administering these compounds, glucose homeostasis in Type II diabetes is effectively regulated.
Career Highlights
Fatima Emitsel Yakubu-Madus is a valued member of Eli Lilly and Company, where she continues to drive innovation in the field of pharmaceuticals. Her dedication to advancing diabetes treatment has garnered recognition within the industry, positioning her as a key figure in the development of cutting-edge therapies.
Collaborations
Yakubu-Madus collaborates closely with esteemed colleagues such as Lawrence E Stramm and William Terry Johnson at Eli Lilly and Company. Together, they form a dynamic team that is at the forefront of pioneering new solutions to address complex medical challenges.
Conclusion
In conclusion, Fatima Emitsel Yakubu-Madus's inventive spirit and passion for healthcare innovation have set her apart as a leading inventor in the field of diabetes treatment. Her patents reflect a commitment to improving the lives of patients afflicted with non-insulin dependent diabetes, showcasing her as a driving force behind transformative medical advancements.